These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 12376557)

  • 1. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.
    Nagy P; Vereb G; Sebestyén Z; Horváth G; Lockett SJ; Damjanovich S; Park JW; Jovin TM; Szöllosi J
    J Cell Sci; 2002 Nov; 115(Pt 22):4251-62. PubMed ID: 12376557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
    Lu Y; Zi X; Zhao Y; Pollak M
    Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping ErbB receptors on breast cancer cell membranes during signal transduction.
    Yang S; Raymond-Stintz MA; Ying W; Zhang J; Lidke DS; Steinberg SL; Williams L; Oliver JM; Wilson BS
    J Cell Sci; 2007 Aug; 120(Pt 16):2763-73. PubMed ID: 17652160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells.
    Fiddes RJ; Janes PW; Sanderson GM; Sivertsen SP; Sutherland RL; Daly RJ
    Cell Growth Differ; 1995 Dec; 6(12):1567-77. PubMed ID: 9019162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutively tyrosine phosphorylated p52 Shc in breast cancer cells: correlation with ErbB2 and p66 Shc expression.
    Stevenson LE; Frackelton AR
    Breast Cancer Res Treat; 1998 May; 49(2):119-28. PubMed ID: 9696394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells.
    Qiu Y; Ravi L; Kung HJ
    Nature; 1998 May; 393(6680):83-5. PubMed ID: 9590694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells.
    Sottocornola E; Misasi R; Mattei V; Ciarlo L; Gradini R; Garofalo T; Berra B; Colombo I; Sorice M
    FEBS J; 2006 Apr; 273(8):1821-30. PubMed ID: 16623716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-dependent recruitment of the ErbB4 signaling complex into neuronal lipid rafts.
    Ma L; Huang YZ; Pitcher GM; Valtschanoff JG; Ma YH; Feng LY; Lu B; Xiong WC; Salter MW; Weinberg RJ; Mei L
    J Neurosci; 2003 Apr; 23(8):3164-75. PubMed ID: 12716924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
    Vijapurkar U; Kim MS; Koland JG
    Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
    Sak MM; Szymanska M; Bertelsen V; Hasmann M; Madshus IH; Stang E
    Carcinogenesis; 2013 Sep; 34(9):2031-8. PubMed ID: 23698633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
    Holbro T; Beerli RR; Maurer F; Koziczak M; Barbas CF; Hynes NE
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8933-8. PubMed ID: 12853564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment.
    Váradi T; Roszik J; Lisboa D; Vereb G; Molina-Guijarro JM; Galmarini CM; Szöllosi J; Nagy P
    Eur J Pharmacol; 2011 Sep; 667(1-3):91-9. PubMed ID: 21658382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homo- and Heteroassociations Drive Activation of ErbB3.
    Váradi T; Schneider M; Sevcsik E; Kiesenhofer D; Baumgart F; Batta G; Kovács T; Platzer R; Huppa JB; Szöllősi J; Schütz GJ; Brameshuber M; Nagy P
    Biophys J; 2019 Nov; 117(10):1935-1947. PubMed ID: 31653451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
    Muthuswamy SK; Gilman M; Brugge JS
    Mol Cell Biol; 1999 Oct; 19(10):6845-57. PubMed ID: 10490623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Dipole Potential Modifies the Clustering and Ligand Binding Affinity of ErbB Proteins and Their Signaling Efficiency.
    Kovács T; Batta G; Hajdu T; Szabó Á; Váradi T; Zákány F; Csomós I; Szöllősi J; Nagy P
    Sci Rep; 2016 Oct; 6():35850. PubMed ID: 27775011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
    Mocanu MM; Fazekas Z; Petrás M; Nagy P; Sebestyén Z; Isola J; Tímár J; Park JW; Vereb G; Szöllosi J
    Cancer Lett; 2005 Sep; 227(2):201-12. PubMed ID: 16112423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.